Adoptive immunotherapy involves stimulation of tumor-specific T cells, ex vivo (outside the body), followed by transfer of expanded numbers of activated T cells back into patients. Current approaches to treatment of multiple myeloma have all been stymied secondary to the impact of the disease on the immune response. We propose to use an engineered artificial Antigen Presenting Cell (APC) with the goal of replacing the use of autologous dysfunctional APC for adoptive immunotherapy for multiple myeloma. Therefore, the work proposed in this application will enable advances in adoptive immunotherapy for treatment of multiple myeloma.